Cargando…
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
BACKGROUND: Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK(+)) T cell lymphoma is an aggressive neoplasm. NPM-ALK, an oncogenic tyrosine kinase, plays a critical role in this lymphoma. Recently, selective ALK inhibitors have emerged as a first-line therapy for this neoplasm. Unfortunat...
Autores principales: | George, Bhawana, George, Suraj Konnath, Shi, Wenyu, Haque, Abedul, Shi, Ping, Eskandari, Ghazaleh, Axelson, Magnus, Larsson, Olle, Kaseb, Ahmed O., Amin, Hesham M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657048/ https://www.ncbi.nlm.nih.gov/pubmed/31340850 http://dx.doi.org/10.1186/s13045-019-0768-8 |
Ejemplares similares
-
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023) -
TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK
(+) T‐cell lymphoma
por: Shi, Wenyu, et al.
Publicado: (2017) -
The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014) -
The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma
por: Vishwamitra, Deeksha, et al.
Publicado: (2015) -
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)